View More Recent Stories

May 21, 2021 06:35PM CORRECTING and REPLACING: Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting
May 21, 2021 06:34PM CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting
May 19, 2021 05:19PM Nanobiotix (NBTX) Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3
May 19, 2021 05:18PM Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society f
May 12, 2021 04:15PM Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
May 11, 2021 04:15PM NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
Apr 29, 2021 04:49PM NANOBIOTIX Announces First Quarter Operational and Financial Updates
Apr 28, 2021 04:15PM NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
Apr 12, 2021 12:00PM Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
Apr 7, 2021 06:27PM NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Mar 17, 2021 05:15PM NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
View More Recent Stories